Achema middle east

Lifebit partners with NIHR Cambridge Biomedical Research Centre to launch the CYNAPSE platform for next-generation genomics research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
- Advertisement -

Lifebit announces a long-term partnership where Lifebit’s technology, Lifebit CloudOS, will power a cloud-based Trusted Research Environment (TRE) to serve as the scalable and secure data management and analysis platform for researchers at the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC).

As one of the leading UK biomedical research organisations, the NIHR Cambridge BRC maintains a secure source of fully consented clinico-genomic data from patients with chronic diseases and cancer. This biomedical data holds huge potential for health researchers to unlock discoveries on disease, supporting recent breakthroughs such as the development of clinical algorithms to guide precision cancer treatments.

With the launch of CYNAPSE, the NIHR Cambridge BRC joins a growing number of research organisations who are standing up TREs that make use of Lifebit’s pioneering federated technology, designed to take researcher’s computation and analysis to where the data resides, to make sensitive biomedical data securely accessible. Other examples include Genomics England and the Hong Kong Genome Institute.

This news comes in the wake of an announcement of the DARE UK consortium effort between Genomics England, NIHR Cambridge BRC, Eastern AHSN, Cambridge University Health Partners and Lifebit that will see Lifebit’s unique federated technology bridge the TREs of these leading organisations.

“Lifebit is proud to be delivering this next generation federated research platform, which will allow NIHR Cambridge BRC researchers to more effectively collaborate at scale and drive a new wave of connected data here in the UK and globally, accelerating research impact and advancements in patient care.” said Thorben Seeger, Lifebit CBDO.

About Lifebit Biotech, Ltd.

Lifebit builds enterprise data platforms for use by organisations with complex and sensitive biomedical datasets. Lifebit’s patented federated technology securely unlocks access to biomedical data. From providing Trusted Research Environments for national precision medicine programmes to enabling pharmaceutical companies to discover new drug targets faster, Lifebit empowers customers to transform how they leverage sensitive biomedical data.

About NIHR
The mission of the National Institute for Health Research (NIHR) is to improve the health and wealth of the nation through research. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.

About NIHR Cambridge Biomedical Research Centre
Based within the most outstanding NHS and University partnerships in the country, the Biomedical Research Centres are leaders in scientific translation. Located on the Cambridge Biomedical Campus, they receive substantial levels of funding from the National Institute for Health Research (NIHR) to translate fundamental biomedical research into clinical research that benefits patients and they are early adopters of new treatments.

Latest stories

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »